Table II.
Clinical features of 177 patients with hepatocellular carcinoma according to YTHDF1 and YTHDF2 expression.
| YTHDF1 expression (n=172)a | YTHDF2 expression (n=174)b | |||||
|---|---|---|---|---|---|---|
| Variables | Low (n=108) | High (n=64) | P-value | Low (n=137) | High (n=37) | P-value |
| Age, years | ||||||
| <65 | 50 | 34 | 0.43 | 67 | 18 | 0.98 |
| ≥65 | 58 | 30 | 70 | 19 | ||
| Sex | ||||||
| Female | 14 | 13 | 0.28 | 22 | 6 | 0.98 |
| Male | 94 | 51 | 115 | 31 | ||
| Virus infection | ||||||
| Others | 44 | 25 | 0.87 | 58 | 13 | 0.46 |
| HCV | 64 | 39 | 79 | 24 | ||
| Albumin, g/dl | ||||||
| ≥3.5 | 85 | 54 | 0.54 | 110 | 30 | 0.98 |
| <3.5 | 22 | 10 | 26 | 7 | ||
| NA | 1 | 0 | 1 | 0 | ||
| PT, % | ||||||
| ≥70 | 91 | 57 | 0.50 | 114 | 34 | 0.29 |
| <70 | 16 | 7 | 22 | 3 | ||
| NA | 1 | 0 | 1 | 0 | ||
| ICG-R15, % | ||||||
| <15 | 58 | 35 | 0.91 | 75 | 19 | 0.15 |
| ≥15 | 19 | 12 | 21 | 11 | ||
| NA | 31 | 17 | 41 | 7 | ||
| Liver cirrhosis | ||||||
| Negative | 72 | 39 | 0.51 | 90 | 20 | 0.25 |
| Positive | 36 | 25 | 47 | 17 | ||
| Child-Pugh classification | ||||||
| A | 100 | 61 | 0.74 | 128 | 35 | 0.91 |
| B | 7 | 3 | 8 | 2 | ||
| NA | 1 | 0 | 1 | 0 | ||
| Liver damage | ||||||
| A | 84 | 54 | 0.53 | 110 | 29 | 0.80 |
| B or C | 19 | 9 | 22 | 7 | ||
| NA | 5 | 1 | 5 | 1 | ||
| Tumour number | ||||||
| Solitary | 86 | 48 | 0.57 | 109 | 27 | 0.38 |
| Multiple | 22 | 16 | 28 | 10 | ||
| Tumour size, cm | ||||||
| <2 | 14 | 10 | 0.82 | 17 | 6 | 0.79 |
| ≥2 | 78 | 50 | 100 | 29 | ||
| NA | 16 | 4 | 20 | 2 | ||
| AFP, ng/ml | ||||||
| <20 | 58 | 35 | 0.91 | 68 | 25 | 0.06 |
| ≥20 | 48 | 28 | 67 | 11 | ||
| NA | 2 | 1 | 2 | 1 | ||
| Differentiation | ||||||
| Good or moderate | 98 | 56 | 0.77 | 121 | 35 | 0.08 |
| Poor | 8 | 6 | 14 | 0 | ||
| NA | 2 | 2 | 2 | 2 | ||
| Growth form | ||||||
| Expansive | 88 | 54 | 0.52 | 114 | 31 | 0.42 |
| Infiltrative | 18 | 8 | 22 | 3 | ||
| NA | 2 | 2 | 1 | 3 | ||
| Formation of capsule | ||||||
| Positive | 70 | 52 | 0.02 | 97 | 27 | 0.84 |
| Negative | 38 | 12 | 40 | 10 | ||
| Infiltration to capsule | ||||||
| Negative | 52 | 22 | 0.08 | 57 | 17 | 0.71 |
| Positive | 55 | 42 | 79 | 20 | ||
| NA | 1 | 0 | 1 | 0 | ||
| Septal formation | ||||||
| Positive | 74 | 42 | 0.61 | 98 | 19 | 0.02 |
| Negative | 31 | 21 | 36 | 17 | ||
| NA | 3 | 1 | 3 | 1 | ||
| Serosal invasion | ||||||
| Negative | 85 | 50 | 0.69 | 107 | 31 | 0.81 |
| Positive | 19 | 14 | 26 | 6 | ||
| NA | 4 | 0 | 4 | 0 | ||
| Portal vein or hepatic vein invasion | ||||||
| Negative | 80 | 45 | 0.60 | 101 | 26 | 0.68 |
| Positive | 28 | 19 | 36 | 11 | ||
| Surgical margin | ||||||
| Negative | 91 | 53 | 0.66 | 114 | 31 | 0.92 |
| Positive | 15 | 11 | 21 | 6 | ||
| NA | 2 | 0 | 2 | 0 | ||
| Stage | ||||||
| <III | 65 | 42 | 0.62 | 85 | 24 | 0.83 |
| ≥III | 41 | 22 | 50 | 13 | ||
| NA | 2 | 0 | 2 | 0 | ||
a
The data for YTHDF1 expression were not available for 5 patients.
b
The data for YTHDF2 expression were not available for 3 patients. PT, prothrombin time; ICG-R15, indocyanine green 15-min clearance rate; AFP, α-fetoprotein; HCV, hepatitis C virus; YTHDF1/2, YT521-B homology domain family 1/2; NA, not available.